We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




ECG Analysis Platform Detects High Risk AF Patients

By HospiMedica International staff writers
Posted on 15 Apr 2021
A novel system uses 12-lead electrocardiogram (ECG) data to identify patients at high risk of developing atrial fibrillation (AF) within the year.

Developed by Tempus (Chicago, IL, USA), in collaboration with the Geisinger Health System (Geisinger; Danville, PA, USA), the Tempus ECG Analysis Platform evaluates the results of a 12-lead ECG exam administered as part of routine care in order to provide clinicians with insight into a patient's risk of future AF and/or atrial flutter events. More...
The deep neural network algorithm was trained using 1.6 million ECGs from 430,000 patients over 35 years of patient care (among patients without a previous history of AF), who would develop it within 12 months.

In a clinical study held at Geisinger, which was published on February 16, 2021 in Circulation, Tempus ECG Analysis performance exceeded that of current clinical models for predicting AF risk. In addition, 62% of patients without known AF, and who experienced an AF-related stroke within three years were identified as high risk by the model before the stroke occurred. When interpreted in conjunction with other clinical information, the platform could help clinicians pursue early and proactive diagnoses for improved clinical management of these conditions and their associated health risks.

“Every year, hundreds of millions of routine ECGs are performed in the United States to detect cardiac abnormalities,” said Joel Dudley, PhD, chief scientific officer of Tempus. “We are making ECGs smarter so that they can identify the risk of future, highly treatable clinical events of interest, such as atrial fibrillation, thus enabling clinicians to act earlier in the course of disease and improve patient outcomes.”

“Not only can we now predict who is at risk of developing atrial fibrillation, but this work shows that the high risk prediction precedes many AF-related strokes,” said Brandon Fornwalt, MD, PhD, co-senior author of the study and chair of Geisinger's Department of Translational Data Science and Informatics. “With that kind of information, we can change the way these patients are screened and treated, potentially preventing such severe outcomes. This is huge for patients.”

In patients with AF, rapid, disorganized electrical signals cause the atria to quiver, interrupting the normal synchronized rhythm between the atria and the ventricles. As a result, the ventricles may beat fast and without a regular rhythm, leading to blood clots, strokes, heart failure, and other heart-related complications.

Related Links:
Tempus
Geisinger Health System



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ultrasound Needle Guidance System
SonoSite L25
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.